Announcements Trials

Browse Landscape

Phase

Phase NA 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9 Prostatic Neoplasms 8 Neoplasms 5 Lung Neoplasms 5 Head and Neck Neoplasms 5 Leukemia, Myeloid, Acute 4 Hematologic Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Recurrence 2 Pulmonary Disease, Chronic Obstructive 2 Neoplasm Metastasis 2 Lymphoma, Follicular 2 Leukemia 2 Colonic Neoplasms 2 COVID-19 2 Xerostomia 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Triple Negative Breast Neoplasms 1 Teratoma 1 Stroke 1 Stomatitis 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1

Interventions

Megestrol Acetate 5 anamorelin 1 Standard of Care 1 Radiotherapy 1 Olanzapine 1 Melatonin 1 Infliximab 1 Ibuprofen 1 Etanercept 1 Eicosapentaenoic Acid 1 Docetaxel 1 Dietary Supplements 1 Cyproheptadine 1 Creatine 1 Counseling 1 Caseins 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cachexia × Standard of Care × Clear all

NCT02330926 2025-08-29

MENAC

Norwegian University of Science and Technology

Phase 3 Completed

Cachexia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡